Uploaded May 2026 | Updated September 2026, 1 week ago
This Grand Rounds, sponsored by our Division of Endocrinology and Metabolism, will examine the American Thyroid Association’s 2025 guidelines and their implications for the care of patients with thyroid cancer. Matthew Ringel, an expert in endocrine-related cancers and a visiting professor from The Ohio State University College of Medicine, will discuss evolving approaches to early-stage disease, the role of molecular testing in diagnosis and treatment planning, and management strategies for radioiodine-resistant disease. The session will highlight practical considerations for applying guideline-based care across diverse clinical presentations.
Speaker:
Matthew Ringel, MD, is the founding chair of the Department of Molecular Medicine and Therapeutics at The Ohio State University College of Medicine, where he holds the Ralph W. Kurtz Endowed Chair. He is the deputy director for basic research at the OSU Comprehensive Cancer Center and a founding co-director of the Center for Cancer Engineering. His research has advanced understanding of the signaling pathways that drive thyroid cancer progression and therapeutic resistance, as well as the genetic factors that predispose patients to thyroid cancer. Ringel is a former editor-in-chief of Endocrine-Related Cancer and served as co-chair of the 2025 American Thyroid Association Thyroid Cancer Guidelines.
Program:
Allison Bond, MD: Introduction
1:12-47:45 — Matthew Ringel, MD
47:45-59:18 — Q&A
See previous Medical Grand Rounds:
May 14: Lead from Where You Stand: How to Advocate forYour Patients, Your Profession, and Yourself
• youtu.be/tuNR8Rc3ygc
May 5: Hollander Rounds: A Clinical Problem-Solving Case
• youtu.be/v5OObq-Ocp4
April 28: Autonomy, Trust, and the Changing Landscape of Procedural Training and Expertise
• youtu.be/JxO2r3FlSCU
April 21: Autonomy, Trust, and the Changing Landscape of Procedural Training and Expertise
• youtu.be/JxO2r3FlSCU
This Grand Rounds, sponsored by our Division of Endocrinology and Metabolism, will examine the American Thyroid Association’s 2025 guidelines and their implications for the care of patients with thyroid cancer. Matthew Ringel, an expert in endocrine-related cancers and a visiting professor from The Ohio State University College of Medicine, will discuss evolving approaches to early-stage disease, the role of molecular testing in diagnosis and treatment planning, and management strategies for radioiodine-resistant disease. The session will highlight practical considerations for applying guideline-based care across diverse clinical presentations.
Speaker:
Matthew Ringel, MD, is the founding chair of the Department of Molecular Medicine and Therapeutics at The Ohio State University College of Medicine, where he holds the Ralph W. Kurtz Endowed Chair. He is the deputy director for basic research at the OSU Comprehensive Cancer Center and a founding co-director of the Center for Cancer Engineering. His research has advanced understanding of the signaling pathways that drive thyroid cancer progression and therapeutic resistance, as well as the genetic factors that predispose patients to thyroid cancer. Ringel is a former editor-in-chief of Endocrine-Related Cancer and served as co-chair of the 2025 American Thyroid Association Thyroid Cancer Guidelines.
Program:
Allison Bond, MD: Introduction
1:12-47:45 — Matthew Ringel, MD
47:45-59:18 — Q&A
See previous Medical Grand Rounds:
May 14: Lead from Where You Stand: How to Advocate forYour Patients, Your Profession, and Yourself
• youtu.be/tuNR8Rc3ygc
May 5: Hollander Rounds: A Clinical Problem-Solving Case
• youtu.be/v5OObq-Ocp4
April 28: Autonomy, Trust, and the Changing Landscape of Procedural Training and Expertise
• youtu.be/JxO2r3FlSCU
April 21: Autonomy, Trust, and the Changing Landscape of Procedural Training and Expertise
• youtu.be/JxO2r3FlSCU
